By Quoth The Raven Research, QTR
On Friday, QTR was given two new nuggets of information about our friends over at Herbalife Ltd. (NYSE:HLF).
The first was that according to a source close to the matter, the company’s EVP of Finance in China has left the company. This is unconfirmed by QTR so far, though I have had a second source echo that he found out the same. Despite this, I always work to verify on my own and will keep reading informed of new developments on my Twitter.
I am working to confirm this detail over the weekend and, if its true, it will be the second Herbalife executive from China to hit the road in just over a couple of weeks. If you have information on this development, you can always shoot me an e-mail at [email protected].
You may recall that QTR published a piece last year linking Herbalife to liver damage. You can read that full article here. In that article, I stated:
- A Journal of Hepatology scholarly article from 2007 concluded from tests in Israel that “an association between intake of Herbalife products and acute hepatitis was identified in Israel”
- Several additional scholarly journal articles have been written about the potential hepatoxicity of Herbalife’s products
- Similar reports were echoed out of Mexico last year before being refuted very quickly
- Herbalife paid Barry Minkow – the last major critic who looked at the lead content in their products – $300,000 for undisclosed reasons in a settlement
The second piece I came across just this week was a news article published in El Espectador, a Colombian online newsmagazine. The article (translated using Google), has the following headline:
The El Espectador article goes on to say:
You can read the full article here.
Existe evidencia médica que relaciona productos de Herbalife con daño en el hígado. Nutricionistas profesionales advierten sobre los riesgos.
